N/A N=26 Dual Energy Cone-Beam Computed Tomography (DE-CBCT) Assessment of Jaw Bone Density
Dental Diseases
Primary: Bone Density Assessment — 0.48; 0.46 g/cc
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 4 N=12 Effect of Parathyroid Hormone (PTH) and Weight-Bearing on Bone in Spinal Cord Injury (SCI)
Osteoporosis · Bone Loss · Spinal Cord Injury
Primary: BMD at Left Total Hip — 0.02 % change in BMD (gm/cm2) from baseline
N/A N=1,011 Point-of-care Osteoporosis Diagnostics With Bindex® Pocket Size Instrument and FRAX
Osteoporosis
Primary: Sensitivity of the Density Index Against Dual Energy X-ray Absorptiometry for Detecting Osteoporosis — 93.7; 100 percentage of true positives
N/A N=36 Texture Analysis for Postmenopausal Osteoporosis
Osteoporosis · Osteopenia
Primary: Changes in Lumbar Spine BMD +/- Treatment With Alendronate — 5.28; -1.48 Percent Change
N/A N=94 Bone Health in Facioscapulohumeral Muscular Dystrophy
Facioscapulohumeral Muscular Dystrophy
Primary: Bone Mineral Density in FSHD — -0.4 z-score
N/A N=93 Bone Structure and Strength Evaluated by Extreme-CT Scan Before and After Treatment of Hyper- and Hypothyroidism
Hyperthyroidism · Hypothyroidism
Primary: Thyroid Extreme CT — 0.89; 1.16 mm
Phase 3 N=77 Bone Loss in Women With Anorexia Nervosa
Anorexia Nervosa
Primary: Bone Mineral Density — 3.2; -0.6 percent change — p=<0.0001
N/A N=44 Blood Flow and Bone Density in Healthy Adult Women
Bone Loss · Hypotensive · Lower Limb Fluid Pooling
Primary: Bone Density of Proximal Femur — -0.133; -.675; 1.3 percent change in bone density
N/A N=86 Longitudinal Effects of Denosumab on Trabecular Bone Score and Femur Strength Index
Osteoporosis · Bone Fracture
Primary: Proportion of Change in Mean Trabecular Bone Score — .00238 Proportion of change
Phase 4 N=6 Bone Histomorphometry in Postmenopausal Men and Women With Osteoarthritis Undergoing Total Hip Replacement
Osteoporosis
Primary: Percentage of Participants With Modeling Based Bone Formation in the Femoral Neck — 100 percentage of participants
N/A N=22 Impact of Vitamin D Supplementation on Lactation Associated Bone Loss
Osteoporosis
Primary: Change in Bone Mineral Density (BMD) in HIP at 6 Months — -0.041; 0.011 grams/cm^2
Phase 3 N=161 Study of the Effect of Once a Week Risedronate on the Microstructure of Tibia and Radius Using a New Scanning Method
Osteopenia
Primary: Trabecular Bone Volume to Tissue Volume at Distal Radius, Percent Change From Baseline to Month 12 — -1.486; -1.255 Percent Change — p=0.7096
Phase 2 N=412 Determine the Efficacy, Safety and Tolerability of Denosumab (AMG 162) in the Treatment of Postmenopausal Women With Low Bone Mineral Density
Low Bone Mineral Density
Primary: Lumbar Spine Bone Mineral Density Percent Change From Baseline at Month 12 for the Placebo and Denosumab Arms — -0.81; 4.41; 4.71; 6.69 Percent change — p=<0.001
N/A N=80 Micromechanical Modeling Using Low Magnitude Mechanical Stimulation
Bone Alteration
Primary: Change in Distal Tibia Bone Quality — 1.121; -2.141 percentage of change — p=0.0481
Phase 2 N=10 Healthy Body, Healthy Bones After Bariatric Surgery Trial
Bariatric Surgery Candidate · Bone Loss · Bone Resorption
Primary: Change in Hip Bone Mineral Density (BMD) — 0; -.03 g/cm2
Phase 2 N=80 Parathyroid Hormone (PTH) for Osteoporosis in Postmenopausal Women
Postmenopausal Osteoporosis · Osteoporosis
Primary: Changes in Indices of Bone Turnover — 4418; 3696; 956; 822 months*(ng/ml - baseline ng/ml)
Phase 2 N=61 Bone Mass and Strength After Kidney Transplantation
End Stage Renal Disease · Kidney Transplantation · Bone Loss
Primary: Percent Change in Bone Density From Pre to Post-calcitriol Treatment Compared to Placebo as Assessed by Both Standard Methodologies — -0.81; -0.70 percent change
Phase 4 N=53 Alendronate Prevents Microarchitectural Deterioration of Trabecular Bone in Early Postmenopausal Women
Osteopenia · Osteoporosis
Primary: Mean % Change From Baseline in Trabecular Number (Tb.N) by HR-pQCT — 2.1; -0.6; 0.9; 4.1 Percent change
N/A N=7,749 Patient Activation After DXA Result Notification
Osteoporosis · Bone Diseases, Metabolic
Primary: Guideline Concordant Osteoporosis Therapy — 2537; 2477 Participants
Phase 2 N=61 Effect of Teriparatide, Vibration and the Combination on Bone Mass and Bone Architecture in Chronic Spinal Cord Injury
Spinal Cord Injury · Bone Loss · Osteoporosis
Primary: Bone Mineral Density BMD of the Total Hip as Assessed by DXA. — 0.66; 0.63; 0.64; 0.65 g/cm^2 — p=0.84
Phase 3 N=79 A High-resolution Peripheral Quantitative Computed Tomography Study in Postmenopausal Women Previously Treated With Denosumab
Low Bone Mass · Low Bone Mineral Density · Osteoporosis
Primary: Percent Change From the Parent Study Baseline in Cortical Thickness at the Distal Radius by HR-pQCT — -5.5; -1.8 Percent change — p=0.0766
N/A N=18 Enhancing Skeletal Adaptations to PTH and Exercise
Exercise · Bone Resorption · Bone Formation
Primary: Change in C-terminal Peptide of Type 1 Collagen (CTX) — 0.03; 0.03; 0.05; 0.03 ng/mL
Phase 3 N=75 Effects of Anorexia Nervosa on Peak Bone Mass
Anorexia Nervosa
Primary: Change in Bone Density Over a 12-month Period — 0.045; 0.280 score on a scale — p=.109
Phase 2 N=68 Bone Mineral Density Effects of Zoledronate in Postmenopausal Women With Breast Cancer
Breast Cancer
Primary: Change in Bone Mineral Density (BMD) From Baseline to 1 Year — 0.048; 0.007; 0.014; 0.005 grams per cubic centimeter
Phase 2 N=154 A Study of LY2541546 in Women With Low Bone Mineral Density
Osteoporosis
Primary: Change From Baseline to 52 Week Endpoint in Lumbar Spine Bone Mineral Density (BMD) — 0.065; 0.115; 0.142; 0.054 g/cm^2
Phase 3 N=424 A Severity-Adapted Clinical Trial of Diminished Bone Mineral Density in Acute Lymphoblastic Leukemia Survivors
Leukemia, Lymphoblastic, Acute · Osteoporosis
Primary: Effect of Taking Calcium and Vitamin D Supplements on Bone Mineral Density (BMD) — -0.95; -0.97; -0.87; -1.04 Z-Score — p=0.86
N/A N=739 Jump-In: Building Better Bones
Adolescent Development
Primary: Baseline Total Volumetric Bone Density at the Femur 4% Site — 277.25; 270.79 milligrams per cubic centimeter (mg/ccm)
N/A N=25 Evaluation of the Trabecular Metal™ Revision Hip Cup Using Bone Mineral Density (DEXA)
Revision, Joint
Primary: Periprosthetic Bone Mineral Density (BMD) of Hip — 1.63; 1.64; 1.85; 1.64 g/cm^2
Phase 2 N=50 Study Evaluating Changes In Bone Mineral Density (BMD), And Safety Of Rhbmp-2/CPM In Subjects With Decreased BMD
Osteoporosis
Primary: Change From Baseline in Bone Mineral Density (BMD) Measured by Dual-Energy X-ray Absorptiometry (DXA) — -0.0026; 0.1299; 0.1196; -0.0029 gram per centimeter squared…
Phase 4 N=69 Effects of Teriparatide or Denosumab on Bone in Postmenopausal Women With Osteoporosis
Osteoporosis
Primary: Change From Baseline to 3 Months in Mineralizing Surface (MS) /Bone Surface (BS) in the Cancellous Compartment (CC) of the Iliac Crest Bone Biopsies — 12.43; -2.51…